Haduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan Stanley

Trevi Therapeutics Inc. (NASDAQ:TRVI) is one of the best multibagger stocks to invest in right now. On August 21, Morgan Stanley’s Judah Frommer initiated coverage of the stock with an Overweight rating and an $18 price target. The Overweight call is based on Haduvio, the company’s extended-release formulation of nalbuphine, which is being developed as a treatment for chronic cough.

Haduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan Stanley

Frommer said Haduvio stands out in a market where existing therapies either offer limited benefit or pose risks such as abuse and respiratory complications. He highlighted its potential to meet a large unmet need for patients with persistent cough.

The analyst estimates that Haduvio could become a multi-billion-dollar opportunity for Trevi Therapeutics Inc. (NASDAQ:TRVI), with growing interest in the pharmaceutical industry adding further support. Large-cap peers such as GSK and Merck have already committed to billion-dollar partnerships in the chronic cough space, suggesting Trevi Therapeutics Inc. (NASDAQ:TRVI) could benefit from heightened attention and investment.

Trevi Therapeutics Inc. (NASDAQ:TRVI) is a clinical-stage biopharmaceutical company developing Haduvio to help patients suffering from chronic cough.

While we acknowledge the potential of TRVI to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TRVI and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Most Shorted Stocks Right Now and 10 Best High Beta Stocks To Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.